Edition:
India

Acceleron To Discontinue Development Of Ace-083 In Facioscapulohumeral Muscular Dystrophy


Tuesday, 17 Sep 2019 

Sept 16 (Reuters) - Acceleron Pharma Inc ::ACCELERON ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 TRIAL OF ACE-083 IN PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON PHARMA INC - ACE-083 DID NOT ACHIEVE STATISTICALLY SIGNIFICANT IMPROVEMENTS IN FUNCTIONAL ENDPOINTS RELATIVE TO PLACEBO.ACCELERON PHARMA INC - ACCELERON TO DISCONTINUE DEVELOPMENT OF ACE-083 IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY.ACCELERON PHARMA INC - TOPLINE RESULTS FROM PHASE 2 TRIAL OF ACE-083 IN CHARCOT-MARIE-TOOTH DISEASE EXPECTED IN Q1 2020.ACCELERON PHARMA - TREATMENT WITH ACE-083 IN PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY DID NOT ACHIEVE FUNCTIONAL SECONDARY ENDPOINTS IN PHASE 2 TRIAL.